<?xml version="1.0" encoding="UTF-8"?>
<p>TMC435350 is found to be a novel and specific protease inhibitor by establishing preclinical models and 
 <italic>in vitro </italic>assays. TMC435350 is a potent HCV NS3/4A serine protease inhibitor which displays synergistic effects in combination with IFN-Î± and additive effects with RBV. Additionally, NS5B inhibitors NM-107 and HCV-796 in combination with TMC435350 showed synergism which debates the effectiveness of TMC435350 clinical antiviral therapy against HCV [
 <xref ref-type="bibr" rid="B40">40</xref>].
</p>
